Kantarjian et al53 assessed the efficacy and basic safety of dasatinib, as compared with imatinib, for the 1st-line remedy of CML-CP. Five hundred and nineteen individuals with recently diagnosed CML-CP have been randomly assigned to obtain dasatinib at a dose of one hundred mg the moment each day (259 clients) https://johnnywbflp.fitnell.com/69553539/little-known-facts-about-azd0156